UroGen acquires IconOVir’s oncolytic virus assets
UroGen has initiated several research partnerships to investigate its RTGel technology.
Drug Development
Incyte and Genesis collaborate on small-molecule medicines
X4 and taiba to distribute WHIM syndrome therapy in Middle East
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
New CEOs to join Merck KGaA’s executive board
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
